Fulcrum Therapeutics, Inc.
$3.22
+2.5%Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -2.7).
Valuation inputs: P/E -2.7, earnings yield N/A, momentum +2.5%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -21.5%, ROIC -23.8%).
Profitability stack: net margin 0.0%, ROE -21.5%, ROIC -23.8%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +4.7%, momentum +2.5%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Fulcrum Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Fulcrum Therapeutics, Inc. Fair Value Envelope
Fulcrum Therapeutics, Inc. Profit Bridge
Profitability Analysis
Fulcrum Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Fulcrum Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Fulcrum Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that FULC stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 9.63, with estimates ranging from a low of 3.00 to a high of 25.00.
The consensus 1-year price target stands at 9.63, with estimates ranging from a low of 3.00 to a high of 25.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Risk-Reward Profile
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Fulcrum Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.13M and sold $19.07M worth of FULC shares, resulting in $16.94M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
1.4M
18.90M
-18.9M
-$18.90M
6-9 Months
0
0.00
15.0K
165.50K
-165K
-$165K
9-12 Months
288.0K
2.13M
0
0.00
+2.1M
+$2.13M
Top Buyers
Gould Robert J
Director
$266K
Ezekowitz Alan
Director
$266K
Geraghty James A
Director
$266K
Dorton Katina
Director
$266K
Haviland Kate
Director
$266K
Top Sellers
Ra Capital Management, L.P.
10 Percent Owner
$18.36M
Gould Robert J
Director
$668K
Oltmans Curtis Gale
Officer: Chief Legal Officer
$45K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $16.94M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Insider Participation
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
No Dividend Yield Data
FULC has not reported any dividend yield values in the available annual periods.
fulc Dividend History
Learning Layer
Related Guides
Build conviction on FULC by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.